

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2017

**MERIDIAN BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

<b>Ohio</b>	<b>0-14902</b>	<b>31-0888197</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No. )
<b>3471 River Hills Drive, Cincinnati, Ohio</b>		<b>45244</b>
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code **(513) 271-3700**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective August 8, 2017 the Board of Directors of Meridian Bioscience, Inc. (the "Company") elected John M. Rice to serve as a director until the next annual meeting of shareholders. The Board has determined that Mr. Rice is independent in accordance with guidelines that the Company has adopted, which comply with the listing standards set forth by the Nasdaq Stock Market.

Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Mr. Rice has served as the Director of Life Sciences at CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. He has served on the board of directors of several privately held healthcare companies.

There is no arrangement or understanding between Mr. Rice and any other person pursuant to which Mr. Rice was elected as a director of the Company. There are no transactions in which Mr. Rice has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Pursuant to its 2012 Stock Incentive Plan, on August 8, 2017 the Company granted Mr. Rice options to purchase 12,000 shares of common stock. Mr. Rice will participate in the compensation arrangements for non-employee directors of the Company as described under the heading "Director Compensation" on page 38 in the Company's proxy statement filed with the SEC on December 14, 2016.

The Board has not appointed Mr. Rice to any committees at this time.

A copy of the press release announcing Mr. Rice's election is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release of the Company dated August 8, 2017

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 8, 2017

MERIDIAN BIOSCIENCE, INC.

By: /s/ Melissa A. Lueke

Executive Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)



**For Immediate Release**

**Meridian Bioscience Elects John Rice to the Board of Directors**

CINCINNATI, August 8, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017.

Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Mr. Rice has served as the Director of Life Sciences at CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. He has served on the board of directors of several privately held healthcare companies.

John A. Kraeutler, Chairman and Chief Executive Officer, commented, "With the election of John to the Board of Directors of Meridian Bioscience we have added key strategic and scientific strengths to help guide our future growth. Our Nominating Committee has been working diligently for the last year to add specific skills to the Board. We are very pleased that John has agreed to join our team. I look forward to working with John and our existing directors as we build a strong future for Meridian Bioscience."

**About Meridian Bioscience, Inc.**

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is [www.meridianbioscience.com](http://www.meridianbioscience.com).

**Contact:**

John A. Kraeutler  
Chairman, Chief Executive Officer  
Meridian Bioscience, Inc.  
Phone: 513.271.3700  
Email: [mbi@meridianbioscience.com](mailto:mbi@meridianbioscience.com)

###